PSMA PET Scans May Simplify Prostate Cancer Treatment by Avoiding Unnecessary Pelvic Lymph Node Dissection

Prostate-specific antigen (PSMA) PET scans show promising results in optimizing the treatment of intermediate-risk prostate cancer patients. These scans may help eliminate unnecessary pelvic lymph node dissection (PLND) during radical prostatectomy, reducing complications and saving resources.

The Role of Pelvic Lymph Node Dissection in Prostate Cancer Treatment

Pelvic lymph node dissection has long been considered the gold standard for nodal staging in men with intermediate-risk prostate cancer. However, PLND carries its own set of risks, including complications such as pain, nerve injuries, and blood clots. For some patients, the procedure offers no discernible benefit.

Optimizing Treatment with PSMA PET Scans

A recent study by researchers from the Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, found that PSMA PET scans have a high negative predictive value (NPV) in determining whether prostate cancer has invaded lymph nodes. The publication appeared in Prostate Cancer and Prostatic Diseases on January 6.

“Used correctly, new promising imaging modalities like PSMA-PET may help select the right patients for PLND during [radical prostatectomy],” the lead authors, Dr. Reha-Baris Incesu and Dr. Felix Preisser, wrote.

Study Details and Key Findings

The research involved 371 intermediate-risk patients undergoing radical prostatectomies. Among them, 333 (90%) underwent PLND, while 38 patients (10%) had no PLND. In those patients who underwent PLND, the median number of lymph nodes removed was 16, and the NPV of PSMA-PET for detecting lymph node invasion was 90.1%.

In terms of patient outcomes, the biochemical recurrence-free survival at 36 months was 78.7% for those who underwent PLND versus 76.7% for those who did not, with no significant difference (p = 0.8).

The study concludes that, in intermediate-risk prostate cancer patients with negative nodal status at PSMA-PET, the performance of PLND does not affect short-term oncologic outcome.

Eliminating Unnecessary Treatments

For years, it has remained unclear whether patients spared PLND based on negative PSMA-PET scans suffer worse oncologic outcomes compared to those who undergo PLND. This study addresses this gap in knowledge.

“In consequence, the complication-prone procedure of PLND could be spared in selected intermediate-risk patients with a PSMA PET negative for [lymph node invasion],” the authors concluded.

Benefits for Patients

The use of PSMA PET scans can potentially reduce the number of patients undergoing PLND and its associated complications. By applying these imaging modalities, clinicians can better tailor treatment plans to individual patients, enhancing their quality of life.

While the long-term oncologic outcomes in patients with negative PSMA PET scans require further follow-up, the current findings provide promising recommendations for optimizing treatment practices in intermediate-risk prostate cancer.

Conclusion

The introduction of PSMA PET scans in the evaluation of intermediate-risk prostate cancer could mark a significant shift in treatment strategies. By helping to identify patients who do not require PLND, these imaging modalities offer potential savings in both resources and patient well-being. As more data becomes available, the role of PSMA PET scans in prostate cancer treatment is likely to expand.

Stay informed about the latest developments in cancer treatment, and consider consulting your healthcare provider about the appropriateness of PSMA PET scans for your diagnosis and treatment plan.

If you found this article informative, please don’t hesitate to share it on social media. Subscribe to our newsletter for regular updates on healthcare news and clinical research. We value your thoughts, so feel free to leave a comment below.